Ph 3 Trial of BNT323/DB-1303 Met Primary Endpoint of PFS in HER2+ve Metastatic or Unresectable Breast Cancer September 10, 2025
Radiance Biopharma signs Exclusive License Agreement with Novatim Immune Therapeutics for RB-601™ (KY-0301), the c-MET/EGFR-targeting ADC September 10, 2025
First patient dosed in trial of huCART19-IL18 cells in the treatment of heme cancers September 10, 2025
Tagrisso + chemo demonstrated a median OS of nearly four years in global Ph 3 FLAURA2 trial in EGFR-mutated advanced NSCLC September 10, 2025
FDA grants HERNEXEOS® Breakthrough Therapy Designation in HER2 (ERBB2)m advanced 1L NSCLC September 10, 2025
Silexion Therapeutics Announces Selection of CRO to Support Upcoming Ph 2/3 Clinical Trials for SIL204 September 10, 2025
